💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

US STOCKS-Futures off on European bank rules, data awaited

Published 10/04/2010, 07:21 AM
Updated 10/04/2010, 07:24 AM
GC
-

* Switzerland seeks new requirements on Credit Suisse, UBS

* Microsoft lower after Goldman downgrade

* Sanofi launches Genzyme bid

* Futures down: Dow 47 pts, S&P 4.6 pts, Nasdaq 10.5 pts

By Ryan Vlastelica

NEW YORK, Oct 4 (Reuters) - U.S. stock index futures were lower on Monday after Swiss plans to tighten banking rules weighed on regional markets ahead of a new round of U.S. data.

* Switzerland will seek rules to require global banks UBS AG and Credit Suisse to hold more top-quality capital. The potential regulations, stricter than international standards, could crimp the banks' competitiveness in investment banking.

* U.S.-listed shares of Credit Suisse were off 0.3 percent to $43.13 in premarket trading, while UBS was unchanged at $17.13. The FTSEurofirst 300 index of top shares was down 0.4 percent.

* Concerns about Europe's banking system have been a headwind for U.S. stocks in recent months, even as some improving domestic data eased concerns over a possible double-dip recession.

* Monday's economic data includes pending home sales, durable good orders and factor orders, all for August. Home sales are seen rising 3 percent after rising 5.2 percent in the previous month. The closely watched non-farm payrolls report for September will be released on Friday, and could offer insight into the weak U.S. labor market.

* S&P 500 futures fell 4.6 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures fell 47 points, and Nasdaq 100 futures lost 10.5 points.

* Dow component Microsoft Corp fell 2 percent to $23.90 in premarket trading after Goldman Sachs downgraded the stock to "neutral," in part citing competition from tablet computers.

* French drugmaker Sanofi-Aventis SA launched a hostile bid for Genzyme Corp at $69 per share, taking its offer directly to shareholders after the biotechnology company refused to negotiate.

* Also in deal news, Microsemi Corp, a maker of power management semiconductors, will buy integrated circuit manufacturer Actel Corp for about $430 million. Actel surged 28 percent to $20.50 in light premarket action.

* While no S&P 500 companies were on tap to report results on Monday, this week will mark the unofficial start of the third-quarter reporting season, with Alcoa Inc due on Thursday. Micron Technology Inc, PepsiCo Inc and Monsanto Co are all set to report this week.

* Wall Street extended a rally on Friday, led by gains in natural resource stocks after data in China showed a pickup in manufacturing activity.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.